| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46001397 | BKPyv | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10003622 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10012046 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10008929 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017508 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017509 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017510 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017511 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017512 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10021570 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NR3C2 |
|---|---|
| DrugBank ID | DB00396 |
| Drug Name | Progesterone |
| Target ID | BE0000668 |
| UniProt ID | P08235 |
| Regulation Type | antagonist |
| PubMed IDs | 8282004; 12039699; 8928765; 7588320 |
| Citations | Rupprecht R, Reul JM, van Steensel B, Spengler D, Soder M, Berning B, Holsboer F, Damm K: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 Oct 15;247(2):145-54.@@Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, Diederich S, Bahr V: Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. Eur J Endocrinol. 2002 Jun;146(6):789-99.@@Myles K, Funder JW: Progesterone binding to mineralocorticoid receptors: in vitro and in vivo studies. Am J Physiol. 1996 Apr;270(4 Pt 1):E601-7. doi: 10.1152/ajpendo.1996.270.4.E601.@@Souque A, Fagart J, Couette B, Davioud E, Sobrio F, Marquet A, Rafestin-Oblin ME: The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology. 1995 Dec;136(12):5651-8. doi: 10.1210/endo.136.12.7588320. |
| Groups | Approved; Vet_approved |
| Direct Classification | Gluco/mineralocorticoids, progestogins and derivatives |
| SMILES | [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
| Pathways | Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency; Apparent Mineralocorticoid Excess Syndrome; Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH; 3-beta-Hydroxysteroid Dehydrogenase Deficiency; Corticosterone Methyl Oxidase I Deficiency (CMO I); 11-beta-Hydroxylase Deficiency (CYP11B1); Steroidogenesis; Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency; 17-alpha-Hydroxylase Deficiency (CYP17); Corticosterone Methyl Oxidase II Deficiency (CMO II); 21-Hydroxylase Deficiency (CYP21) |
| PharmGKB | PA451123 |
| ChEMBL | CHEMBL103 |
